Recently major efforts in Alzheimer's disease (AD) research have concentrated on the search for disease-associated biomarkers that can identify people at risk for developing AD, help with early diagnosis, prognosis or therapeutic decision-making, and allow for an expedited evaluation of novel disease-modifying therapies. The current project will use an advanced automated hippocampal segmentation approach based on an adaptive machine-learning algorithm paired with the hippocampal radial atrophy mapping technique to establish the dynamic pattern of hippocampal changes that occur in Alzheimer's disease in 3D. AdaBoost is a widely recognized breakthrough computer vision approach that shows great promise as an objective, reproducible and reliable automated hippocampal segmentation technique. While implementing cutting edge mathematical and statistical concepts, the combined technique provides high throughput and sensitivity to disease-associated hippocampal changes. The main goal of this project is to test the performance, variability, robustness and reproducibility of the approach in very large 1.5T and 3T epidemiological and 1.5T clinical trial datasets and to ultimately establish the AdaBoost/radial atrophy methodology as a potential secondary/surrogate outcome measure for clinical trials in AD and MCI that will overcome many of the limitations imposed by the widely used cognitive batteries such as ceiling and floor effects, fluctuations and learning and practice effects. In addition we will identify the hippocampal morphological changes associated with imminent conversion from MCI to AD and investigate potential cognitive and laboratory biomarker correlations with hippocampal atrophy thus investigating potential disease biosignatures.
If no cure is found, AD will affect as many as 10-16 million Americans by year 2050. Recently major efforts in AD research have concentrated on the search for biomarkers that can identify people at risk as early as possible and assess promising disease-modifying therapies presently being evaluated. The proposed research will further validate and establish a state-of-the-art high throughput automated imaging biomarker for use in epidemiological and clinical trial research.
|Chang, Timothy S; Teng, Edmond; Elashoff, David et al. (2016) Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials. Alzheimer Dis Assoc Disord :|
|Green, Colin; Zhang, Shenqiu (2016) Predicting the progression of Alzheimer's disease dementia: AÂ multidomain health policy model. Alzheimers Dement 12:776-85|
|Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43|
|Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-50|
|Ramirez, Leslie M; Goukasian, Naira; Porat, Shai et al. (2016) Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. Neurobiol Aging 39:82-9|
|Filshtein, Teresa; Beckett, Laurel A; Godwin, Haley et al. (2016) Incident Antipsychotic Use in a Diverse Population with Dementia. J Am Geriatr Soc 64:e44-6|
|Clark, David Glenn; McLaughlin, Paula M; Woo, Ellen et al. (2016) Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment. Alzheimers Dement (Amst) 2:113-22|
|Lin, Amy; Brook, Jenny; Grill, Joshua D et al. (2016) Participant-Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease. Am J Geriatr Psychiatry :|
|Porat, Shai; Goukasian, Naira; Hwang, Kristy S et al. (2016) Dance Experience and Associations with Cortical Gray Matter Thickness in the Aging Population. Dement Geriatr Cogn Dis Extra 6:508-517|
|Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-21|
Showing the most recent 10 out of 651 publications